US 12,404,239 B2
Modulators of BCL6 as ligand directed degraders
Dehua Huang, San Diego, CA (US); Matthew David Alexander, San Diego, CA (US); Brandon Wade Whitefield, San Diego, CA (US); Hunter Paul Shunatona, San Diego, CA (US); Dharmpal S. Dodd, Escondido, CA (US); Deborah S. Mortensen, San Diego, CA (US); Giulianna Miseo, San Diego, CA (US); Natalie Holmberg-Douglas, San Diego, CA (US); Jayce Rhodes, San Diego, CA (US); and Jennifer Griffin, San Diego, CA (US)
Assigned to Celgene Corporation, Princeton, NJ (US); and Bristol-Myers Squibb Company, Princeton, NJ (US)
Filed by Celgene Corporation, Summit, NJ (US); and Bristol-Myers Squibb Company, Princeton, NJ (US)
Filed on Apr. 27, 2023, as Appl. No. 18/140,129.
Claims priority of provisional application 63/336,104, filed on Apr. 28, 2022.
Prior Publication US 2024/0025851 A1, Jan. 25, 2024
Int. Cl. C07D 209/34 (2006.01)
CPC C07D 209/34 (2013.01) 10 Claims
 
1. A compound of the following structural formula:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.